Active Biotech's election committee appointed

LUND, SWEDEN -- (Marketwire) -- 11/15/12 -- In accordance with a decision made by the
Annual General Meeting held on May
10, 2012, the Election Committee shall comprise the representatives for the
three largest shareholders, as per end of September 2012, and the Chairman
of
the Board.

For the 2013 Annual General Meeting, the Election Committee shall propose
Board
members and a Chairman of the Board, and fees to Board members and
auditors. The
following individuals were appointed representatives for the largest
shareholders and, accordingly, are members of the Election Committee:

Under the leadership of the Chairman of the Board, Mats Arnhög, the
Election
Committee shall prepare proposals for the Board of Directors that are to be
presented to and decided upon at the Annual General Meeting on May 15,
2013.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
for
prostate cancer and ANYARA primarily for the treatment of renal cell
cancer. In
addition, laquinimod is in Phase II development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.

Cloud computing budgets worldwide are reaching into the hundreds of billions of dollars, and no organization can survive long without some sort of cloud migration strategy. Each month brings new announcements, use cases, and success stories.